An earlier study shows that an individual with type 2 diabetes is at an enhanced risk of serious health conditions such as heart attacks and stroke due to the low HDL cholesterol levels and the high triglycerides levels.
A study funded by the National Heart, Lung and Blood Institute (NHLBI), Bethesda, the United States shows that the fenofibrate therapy can reduce the risk associated with strokes and heart attacks in the patients with type 2 diabetes even though the patient is with high levels of fat (and triglycerides ), low levels of HDL cholesterol and taking statins medications.
Researchers in the study investigated whether
A follow-up study on 4,640 patients with type 2 diabetes shows that the fenofibrate therapy helps in lowering cardiovascular symptoms in a patient with high triglycerides and low HDL cholesterol levels even though the patient is taking statins medications. Researchers say a randomized controlled trial is required to confirm the current study. The study was published in the JAMA Cardiology.
Fenofibrate : Fenofibrate is being used since 1975. They are a class of amphipathic carboxylic acids and hypolipidemic agents, recommended by the doctors if the patient is unable to take statin drugs. These drugs can lower LDL cholesterol and triglycerides levels in the blood (a risk factor to atherosclerosis - blockage of arteries).
But these medications are less effective compared with statin drugs. But they are effective in controlling other health aspects such as metabolic disorders, hypercholesterolemia (high amounts of cholesterol in the blood) and hypertriglyceridemia (high levels of triglycerides in the blood).
An earlier study shows that the fenofibrate can prevent the microvascular occlusion and thrombosis. Side effects with fenofibrate are a headache, nausea, back pain, arthralgia (joint pain), nasopharyngitis (cold - infection in nose and throat), myalgia (muscle pain), diarrhoea (or diarrhea) and respiratory tract infection.
There are drugs for the treatment of symptoms of Parkinson's disease but no drug to prevent the disease. An earlier study shows the metabolic changes at the molecular level are similar in diabetes and in Parkinson's disease. This phenomenon gave interest to the researchers to find out a drug for the prevention of the Parkinson's disease.
Researchers studied more than 120 potential treatments. The study found that the thiazolidinediones drugs such as MSDC-0160 (a drug developed for the treatment of type 2 diabetes) can prevent the root cause of Parkinson's disease.
Researchers conducted trials on the animal models with a MSDC-01600 drug to cure Parkinson's disease. All the models has shown a slowdown in the progression of Parkinson's disease. The MSDC-0160 drug is successful in controlling the functionality of the brain cells by restoring mitochondrial function, leading to a lower death of brain cells and a lower inflammation.
Researchers say that the current drug can be used for the treatment of the patients suffering from cognitive conditions such as Alzheimer's disease and dementia. Now researchers working on a human trial as early as possible. Part of the study was funded by the Cure Parkinson's Trust, a London based charity. Senior author of the study is Dr. Patrik Brundin, MD, Ph.D., and the study was published in the Science Translational Medicine.
Parkinson's disease : Parkinson's disease is a damage to the central nervous system causing a drop in dopamine (a neurotransmitter) levels. Damage to the nerves affects the function of muscles, speech, tremors, stiffness and loss of balance. This disease affects mostly the people aged between 50 and 60 years.
Thiazolidinediones : Oral hypoglycemic drugs are being used for the treatment of type 2 diabetes. Combination drugs of thiazolidinediones are also available. These drugs can lower the insulin resistance in fat and muscle of the body. These drugs may lower the triglycerides and improve HDL levels. Call a doctor if the patient is using thiazolidinediones drug experience side effects such as the breathing trouble, chest pain, nausea, vomiting and swelling (in lips, face, throat or tongue).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.